Development of a Liquid Chromatography–Tandem Mass Spectrometry Method for Oxylipin Analysis and Its Application to Children’s Plasma
by
, and
Yonghan Li
1,†,
Siddabasave Gowda B. Gowda
2,3,†
,
Divyavani Gowda
3,
Atsuko Ikeda
3,4,
Yu Ait Bamai
4, 
Rahel Mesfin Ketema
3,4,
Reiko Kishi
4,
Hitoshi Chiba
5 and
Shu-Ping Hui
3,*
1
Graduate School of Health Sciences, Hokkaido University, Kita-12, Nishi-5, Kita-ku, Sapporo 060-0812, Japan
2
Graduate School of Global Food Resources, Hokkaido University, Kita-9, Nishi-9, Kita-Ku, Sapporo 060-0809, Japan
3
Faculty of Health Sciences, Hokkaido University, Kita-12, Nishi-5, Kita-ku, Sapporo 060-0812, Japan
4
Center for Environmental and Health Sciences, Hokkaido University, Kita-12, Nishi-7, Kita-ku, Sapporo 060-0812, Japan
5
Department of Nutrition, Sapporo University of Health Sciences, Nakanuma Nishi-4-2-1-15, Higashi-ku, Sapporo 070-0894, Japan
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Diagnostics 2025, 15(15), 1870; https://doi.org/10.3390/diagnostics15151870
Submission received: 4 June 2025
/
Revised: 13 July 2025
/
Accepted: 21 July 2025
/
Published: 25 July 2025
(This article belongs to the Special Issue Recent Advances in Pediatric Laboratory Medicine)
Abstract
Background/Objectives: Oxylipins, a family of oxygenated natural products derived from polyunsaturated fatty acids (PUFAs), play crucial roles in various physiological processes. Evaluating their levels in vivo helps to reveal their roles in health and disease. Because of the numerous isomers of oxylipins, it is essential to develop efficient and precise analytical methods for their identification and quantification. The objective of this study is to establish a quantitative method for oxylipin analysis and its application to the assessment of oxylipins in children’s plasma, with potential implications for diagnostic use in pediatric populations. Methods: A liquid chromatography–electrospray ionization–tandem mass spectrometry method was developed to quantify 64 oxylipins and four precursor PUFAs within 36 min. The limits of quantification ranged from 0.25 to 50 pg, with most analytes showing recoveries and matrix effects between 85 and 110% and between 90 and 110%, respectively. Intra- and inter-day precision values were within 15%. The established method was applied to plasma samples from children aged 9–12 years (boys = 181; girls = 161) in Hokkaido, Japan, to assess the relation between plasma oxylipin and PUFA levels and age, sex, and body mass index. Results: There was no significant correlation between oxylipin levels and age, sex, or body mass index. However, among the PUFAs, boys had higher eicosapentaenoic acid and arachidonic acid levels than those of girls, with a significant increase in eicosapentaenoic acid levels in the overweight group compared with those in the underweight group. Conclusions: We successfully developed a simple and highly selective method for the analysis of oxylipins in preadolescent children’s plasma samples. Thus, this study provides a foundation for broader application of the developed method to different biological samples in future studies.
1. Introduction
Oxylipins are a diverse and biologically significant family of oxygenated fatty acids derived from polyunsaturated fatty acids (PUFAs), such as arachidonic acid (AA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and linoleic acid (LA) [1,2,3]. The metabolic transformation of PUFAs into oxylipins occurs via several enzymatic pathways, including cyclooxygenases, lipoxygenases, and cytochrome P450 monooxygenases, as illustrated in Figure 1. Bioactive lipids play crucial roles in various physiological and pathophysiological processes, making them essential for biomedical research [1]. The biological importance of oxylipins is underscored by their involvement in regulating inflammation, immunity, and vascular function [1]. Oxylipins can act as signaling molecules that modulate inflammatory responses. For instance, prostaglandins and leukotrienes, which are derived from AA through enzymatic pathways involving cyclooxygenase and lipoxygenase, respectively, are well-known mediators of inflammation and allergic reactions that contribute to the onset and resolution of inflammation [4]. Oxylipins play a significant role in maintaining vascular homeostasis. Epoxyeicosatrienoic acids (EETs), produced by the cytochrome P450 pathway, exhibit vasodilatory properties and contribute to blood pressure regulation. They also possess anti-inflammatory and cardioprotective properties, which highlight their therapeutic potential against cardiovascular diseases [5]. Furthermore, the dysregulation of oxylipin pathways has been implicated in various diseases, including asthma, cardiovascular diseases, cancer, and neurodegenerative disorders. Elevated levels of proinflammatory oxylipins, such as leukotrienes, have been associated with the pathogenesis of asthma and other allergic conditions [6]. Similarly, alterations in the balance between pro- and anti-inflammatory oxylipins have been observed in cardiovascular diseases, contributing to endothelial dysfunction and atherosclerosis [7].
The detection and quantification of oxylipins in plasma are particularly important for pediatric populations, as it aids in the early diagnosis and monitoring of pediatric diseases characterized by inflammation and immune dysregulation, such as asthma, allergies, and autoimmune diseases [8,9]. Additionally, monitoring oxylipins in pediatric plasma enhances our understanding of the potential of dietary interventions and pharmacological treatments [10,11]. Studies have indicated that n-3 (also known as ω-3) fatty acids such as ALA, EPA, and DHA (those having cis-double at C-3 carbon from the end terminal of fatty acids), which are precursors of anti-inflammatory oxylipins, modulate the oxylipin profile and offer protective effects against inflammation and immune dysregulation in children [10,11]. By quantifying oxylipin levels before and after dietary or drug interventions, researchers can evaluate the efficacy of these strategies and optimize treatment plans for pediatric populations.
It is evident in the literature that gas chromatography–mass spectrometry (GC-MS) technique has been used for the analysis of oxylipins [12,13]. However, GC-MS requires extensive sample preparation, including derivatization (typically involving the conversion of polar functional groups into more volatile and thermally stable derivatives that are compatible with gas-phase separation), which can be time-consuming and labor-intensive [14]. Recently, liquid chromatography–mass spectrometry (LC-MS) has emerged as a powerful alternative with several advantages over GC-MS. LC-MS eliminates the need for derivatization, thereby simplifying sample preparation and reducing the risk of oxylipin degradation [15,16]. Furthermore, coupling liquid chromatography with tandem mass spectrometry has significantly enhanced the specificity and sensitivity of oxylipin detection [17,18,19]. This technique allows the simultaneous quantification of multiple oxylipins in complex biological matrices, providing a comprehensive profile of these bioactive lipids [17,18,19].
Oxylipins are key mediators of inflammation, immunity, and vascular function. Establishing reliable and sensitive analytical methods is essential for elucidating their biological roles in the human body. Despite their recognized significance, current studies lack simple extraction and comprehensive oxylipin profiling in pediatric populations. In this study, we developed and optimized an extremely sensitive and selective method for oxylipin detection using liquid chromatography–tandem mass spectrometry coupled with multiple reaction monitoring (MRM). Understanding the levels and composition of oxylipins in children during this critical developmental period is crucial for elucidating the potential impact of these lipid mediators on child health and development. Our study not only fills a gap in the current research but also provides foundational data and novel methodologies for future investigations into the roles of oxylipins in pediatric diseases and health conditions.
2. Materials and Methods
2.1. Materials
The following authentic standards were obtained from Cayman Chemical (Ann Arbor, MI, USA): (±)12(13)-dihydroxy-octadecenoic acid ((±)12(13)-DiHOME), (±)9(10)-DiHOME, 9(S)-hydroxy-octadecadienoic acid (9(S)-HODE), 13(S)-HODE, 13-oxo-octadecadienoic acid, 9-oxo-octadecadienoic acid, (±)12(13)-epoxy-octadecenoic acid, (±)9(10)-epoxy-octadecenoic acid, (±)19(20)-dihydroxy-docosapentaenoic acid ((±)19(20)-DiHDPA), (±)16(17)-DiHDPA, (±)13(14)-DiHDPA, (±)10(11)-DiHDPA, (±)7(8)-DiHDPA, (±)19(20)-epoxy-docosapentaenoic acid ((±)19(20)-EpDPA), (±)16(17)-EpDPA, (±)13(14)-EpDPA, (±)10(11)-EpDPA, (±)7(8)-EpDPA, prostaglandin E3, prostaglandin F3α, 5(S)-hydroxy-eicosapentaenoic acid (5(S)-HEPE), (±)8-HEPE, (±)9-HEPE, (±)11-HEPE, 12(S)-HEPE, 15(S)-HEPE, (±)18-HEPE, (±)8(9)-epoxy-eicosatetraenoic acid ((±)8(9)-EpETE), (±)11(12)-EpETE, (±)14(15)-EpETE, (±)17(18)-EpETE, (±)5(6)-dihydroxy-eicosatetraenoic acid ((±)5(6)-DiHETE), (±)11(12)-DiHETE, (±)8(9)-DiHETE, (±)14(15)-DiHETE, (±)17(18)-DiHETE, (±)4-hydroxy-DHA ((±)4-HDHA), (±)7-HDHA, (±)8-HDHA, (±)10-HDHA, (±)11-HDHA, (±)13-HDHA, 14(S)-HDHA, (±)16-HDHA, 17(S)-HDHA, (±)20-HDHA, 9(S)-hydroxy-octadecatrienoic acid (9(S)-HOTrE), 13(S)-HOTrE, 13(S)-HOTrE(γ), (±)5-hydroxy-eicosatetraenoic acid ((±)5-HETE), (±)8-HETE, (±)11-HETE, (±)12-HETE, (±)15-HETE, (±)5(6)-epoxy-eicosatetraenoic acid ((±)5(6)-EET), (±)8(9)-EET, (±)11(12)-EET, (±)14(15)-EET, 5-oxo-eicosatetraenoic acid (5-OxoETE), 12-OxoETE, 15-OxoETE, prostaglandin F2α, (±)5-iso prostaglandin F2α-VI, 8-iso prostaglandin F2α, AA, DHA, EPA, and LA. Deuterium-labelled internal standards, such as 8-iso prostaglandin F2α-d4, AA-d8, 15(S)HETE-d8, 12(S)HETE-d8, and 5(S)HETE-d8, were also obtained from Cayman Chemical (Ann Arbor, MI, USA).
LC-MS-grade methanol and acetonitrile were purchased from Kanto Chemical Co. (Tokyo, Japan). Acetic acid (LC-MS grade) was obtained from the Fujifilm Wako Pure Chemical Corporation (Osaka, Japan). Butylated hydroxytoluene (BHT), which was used as an antioxidant during lipid extraction, was sourced from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). All standards were dissolved in methanol and stored at −80 °C to maintain their stability.
2.2. Human Samples
Plasma samples were obtained from non-fasting children aged 9–12 years (n = 342; boys = 181; girls = 161) who were part of the Hokkaido Study on Environment and Children’s Health, Hokkaido Cohort [20,21,22,23]. The criteria for selecting participants are detailed in separate publications [24,25]. The surveyed children primarily resided in Sapporo, Hokkaido, and its surrounding areas. They were born between April 2006 and January 2010. On the day of the survey, they attended designated clinics with their guardians, where they underwent blood sampling and measurements of height, weight, and other physical parameters. The study’s objectives and methods were thoroughly explained to both the children and their parents. Written informed consent was obtained from all parents, and assent was obtained from all participating children.
2.3. Extraction of Oxylipins from Plasma Samples
As depicted in Figure 2, a standardized protocol [26] was employed for the quantitative analysis of oxylipin family members in the plasma of children aged 9–12 years. Initially, 50 µL of plasma was mixed with 900 µL of methanol containing 0.01% BHT. This mixture was then incubated in an ice bath for 45 min to precipitate proteins and reduce the enzymatic activity that could degrade oxylipins. Subsequently, the samples were vortexed for 1 min at 3500 rpm to ensure thorough mixing. The samples were then centrifuged at 20,630× g for 10 min at 4 °C to separate the supernatant containing the oxylipins. The resulting supernatant was transferred to a new tube and evaporated at 4 °C to concentrate the oxylipins. The dried residue was re-dissolved in 100 µL of methanol to prepare it for analysis. Finally, a 10 µL aliquot of the reconstituted sample was injected into the LC-MS for quantification.
2.4. LC-MS Analysis
The LC-MS conditions for analysis were meticulously optimized to ensure high sensitivity and specificity. The liquid chromatography system utilized was the Shimadzu UFLC system (Shimadzu, Kyoto, Japan), equipped with a Kinetex column (Phenomenex Torrance, CA, USA, 100 × 2.1 mm, 2.6 µm). The mobile phase flow rate was set to 0.24 mL/min, with the column temperature maintained at 40 °C. Solvent A consisted of water and 0.1% acetic acid, whereas solvent B consisted of a mixture of methanol and acetonitrile (50/50, v/v) with 0.1% acetic acid. The injection volume for each sample was 10 µL. The gradient elution program was as follows: starting with 100% solvent A, the composition was maintained for 6 min, and then changed to 43% solvent A and 57% solvent B over the next 3 min, reaching 34% solvent A and 66% solvent B after 20 min, followed by 24% solvent A and 76% solvent B after 22 min. After 27 min, the eluent was 100% solvent B, which was held for 33 min before returning to the initial conditions at 35 min.
For mass spectrometry measurements, a Thermo Scientific TSQ Quantum Access MAX triple-quadrupole system (Thermo Fisher, San Jose, CA, USA) was employed, operating in the negative ionization mode using HESI-II. Acquisition was performed in MRM mode. Key MS parameters included a spray voltage of 4 kV, vaporizer temperature of 250 °C, sheath gas pressure of 30 arbitrary units, auxiliary gas pressure of 5 arbitrary units, and capillary temperature of 300 °C. The collision pressure was set to 1.5 mTorr with a skimmer offset of −5 V. Tube lens and collision energy were compound-specific, ranging from 60 to 92 V and 15 to 27 eV, respectively. The optimized MS parameters for each analyte are listed in Table 1. Nitrogen was used as the desolvation gas, and argon was used as the collision gas. Data acquisition was performed using the Xcalibur 2.2 software.
2.5. Linearity and Range
The linearity of the oxylipins was assessed using calibration curves prepared from 12 different concentrations of mixed solutions ranging from 0.001 to 100 ng/mL. For the four precursor PUFAs (AA, DHA, EPA, and LA), calibration curves were generated using 19 different concentrations ranging from 0.001 to 20,000 ng/mL. Each calibration level was prepared with 50 ng/mL of an IS for oxylipins and PUFAs, either 8-iso prostaglandin F2α-d4, AA-d8, 15(S)-HETE-d8, 12(S)-HETE-d8, or 5(S)-HETE-d8, selected based on structural or positional similarity to the corresponding analyte. However, not all concentrations were used for each compound. Calibration curves were constructed by plotting the ratio of the analyte area to the internal standard area against the corresponding concentration ratio. The limit of detection (LOD) was determined based on a signal-to-noise ratio of 3, whereas the limit of quantification (LOQ) was defined using a signal-to-noise ratio of 10.
2.6. Accuracy and Precision
To assess the accuracy and precision of the oxylipin quantification, pooled plasma samples were spiked with three concentrations of mixed oxylipin solutions at low (50 ng/mL), medium (75 ng/mL), and high (100 ng/mL) levels (n = 4). The intra-day accuracy was determined by calculating the percentage ratio of the measured mean concentration to the expected concentration for each level. Inter-day accuracy was evaluated by calculating the percentage ratio of the mean concentration measured on the second day to the expected concentration for each level. Both intra-day and inter-day precision were expressed as the relative standard deviation (RSD).
2.7. Recovery and Matrix Effects
Mixed oxylipin solutions at three different concentrations (low, 50 ng/mL; medium, 75 ng/mL; high, 100 ng/mL) and an IS solution (50 ng/mL) were added to methanol (Group A), pre-extraction pooled plasma (Group B), and post-extraction pooled plasma (Group C), with each group tested in quadruplicate (n = 4). Recovery was calculated as the ratio of the mean analyte/internal standard area in Group B to Group A and was expressed as a percentage (B/A × 100%). Matrix effects were assessed by calculating the ratio of the mean analyte/internal standard area in Group C to Group A and were expressed as a percentage (C/A × 100%).
2.8. Blood Test Analysis
The relationship between oxylipin and PUFA levels to hematological parameters was assessed through complete blood cell counts, which were performed by Daiichi Kishimoto Clinical Laboratories Co., Ltd. (Sapporo, Japan) in accordance with standardized protocols for processing and reporting.
2.9. Data Visualization and Statistics
Statistical analyses and data visualization were performed using GraphPad Prism version 9.5.0 software (San Diego, CA, USA). The Shapiro–Wilk test assessed the normality of oxylipin and PUFA concentrations, demonstrating a non-normal distribution (p < 0.05). Subsequent analysis using the Kruskal–Wallis test indicated statistically significant differences among the groups (p < 0.05). Dunn’s multiple comparison test was used to further analyze these differences, with p < 0.05 denoting statistical significance. The Kolmogorov–Smirnov test was employed to analyze a single variable, with significance set at p < 0.05.
3. Results and Discussion
3.1. Optimization of Mass Spectrometry Parameters and Selection of Product Ions
To the best of our knowledge, there is limited research on analyzing oxylipins in the plasma of healthy prepubescent children. While developing our analytical method for oxylipins, we encountered significant challenges similar to those reported in previous studies [27,28]. Firstly, oxylipins consist of many structurally similar isomers, necessitating precise separation by liquid chromatography and accurate detection by mass spectrometry. This structural similarity requires high-resolution techniques for proper identification and quantification. Secondly, the extremely low endogenous concentrations of oxylipins in biological samples present significant hurdles to method sensitivity, requiring advanced analytical techniques capable of detecting trace levels with high accuracy. Finally, the multiple unsaturated double bonds in oxylipin structures render them highly susceptible to oxidation. Thus, stringent precautions must be taken during sample preparation and analysis to preserve stability and integrity and ensure reliable and reproducible results. In this study, BHT was employed as an antioxidant to mitigate sample oxidation, and extended elution times were implemented to ensure adequate separation of isomers. In addition, more distinctive fragment ions were utilized in the triple-quadrupole mass spectrometer, which enhanced the reliability and reproducibility of the analytical results.
In this study, we analyzed 64 oxylipins, including numerous structural isomers with closely related chemical properties, fragmentation patterns, and retention times. For example, within the HETE family, (±)5-HETE, (±)8-HETE, (±)11-HETE, (±)12-HETE, and (±)15-HETE produce a predominant fragment ion [M-18-H]−, as shown in Figure 3A, due to the loss of H2O from the carboxyl group. Despite this ion’s intensity, their close retention times (23.2–24.5 min) make separation challenging. To enhance detection accuracy, we prioritized more distinctive fragmentation ions over the most sensitive ones to avoid isomer interference, such as 319.2/115.0 for (±)5-HETE and 319.2/219.0 for (±)15-HETE.
3.2. Validation of LC-MS Method for Oxylipin Analysis
To ensure the robustness of the analytical method for oxylipin quantification, several validation parameters were evaluated, including retention time, LOD, LOQ, linearity, linear range, and slope, as summarized in Table 2. The retention times were consistent for each oxylipin, indicating reliable chromatographic separation, ranging from 12.36 min for Prostaglandin F3α to 27.81 min for LA. The method demonstrated exceptionally low LODs and LOQs, ranging from 0.1 to 25 pg and 0.25 to 50 pg, respectively, facilitating the detection of trace oxylipin levels. It also exhibited a broad linear range for oxylipin quantification, typically spanning 5–1000 pg, ensuring accurate measurements across a wide concentration spectrum. Most oxylipins displayed outstanding linearity with R2 values exceeding 0.99, with the exception of (±)8-HDHA, which had a slightly lower R2 value of 0.9818.
The recovery rates and matrix effects of various oxylipins at three concentrations (low, medium, and high) are shown in Table 3, which lists the precursor PUFAs and a representative oxylipin group. The recovery rates for oxylipins ranged from approximately 70% to 120%, with most values falling between 85% and 110%, indicating a high extraction efficiency. The matrix effect evaluates the impact of plasma components on the analyte ionization efficiency, showing that the majority of analytes had matrix effects between 90% and 110%. However, a few analytes, such as AA and EPA, displayed matrix effects of approximately 70% at medium and high concentrations, indicating ion suppression. Overall, this method ensures reliable quantification of oxylipins in plasma samples.
The accuracy and precision data obtained from the intra-day and inter-day analyses are detailed in Table 4. We utilized three different concentrations to evaluate the four precursors and representative oxylipins. The majority of the analytes exhibited intra-day and inter-day accuracies ranging from 75% to 110%. The precision was expressed as RSD, which was mostly within 15%. These results confirmed that the method is robust, dependable, and reproducible for the quantification of oxylipins in plasma samples.
3.3. Analysis of Oxylipin and PUFA Levels in Children’s Plasma
The method was successfully applied to determine the baseline concentrations of the target oxylipins in the plasma of children aged 9–12 years. Quality control samples (pooled plasma and IS) were injected eight times during continuous injection. The results demonstrated that the RSDs of the five IS were below 20%, indicating that the analytical method and instrumentation system exhibited excellent repeatability and stability during sample injection. The extracted ion chromatograms (EICs) of oxylipins and PUFAs in plasma and standards are displayed in Figure 3B, and the similar retention times observed in plasma and standards indicate the consistency of this method. Analytes of four PUFAs and four oxylipins (EPA, DHA, AA, LA, (±)12(13)-DiHOME, (±)9(10)-DiHOME, 9(S)-HODE, 13(S)-HODE) were quantified and analyzed based on age, sex, and body mass index (BMI) status. The concentrations of oxylipins and PUFAs for individual samples are provided in Supplementary Materials Table S1.
3.4. Analysis of Oxylipin and PUFA Levels in Children’s Plasma Samples Across Age Groups
The plasma levels of oxylipins and PUFAs in children aged 9–12 years are compared in Figure 4, and their quantified concentrations are detailed in Table 5. Values are reported as median (interquartile range). Overall, the oxylipin concentrations were exceedingly low, with most values falling below 1 ng/mL. By contrast, the levels of PUFAs were several orders of magnitude higher, ranging from hundreds to thousands of ng/mL. Across all age groups, the LA exhibited the highest concentration of analytes. No significant age-related differences were observed between groups. (±)12(13)-DiHOME and (±)9(10)-DiHOME, which are derived from LA by cytochrome P450, play critical roles in inflammation, immune response, and vascular function [29,30]. While another study indicated that n-6 oxylipins, such as 9,10-DiHOME and 12-HETE, increased with age in healthy children aged 1–17 years [8], the narrower age range of our cohort (9–12 years) likely limited the potential for detecting age-related changes, with a median of approximately 0.5 ng/mL. These differences might be due to age-specific stability within the 9–12 age range or ethnic differences, as our study involved children from Hokkaido, Japan, whereas the other study focused on non-Hispanic Caucasians [8].
Similarly, 9(S)-HODE and 13(S)-HODE were not significantly different between the age groups. Oxylipins derived from LA via the lipoxygenase and cyclooxygenase pathways are markers of oxidative stress and inflammation [31,32]. Although studies correlating HODE levels with human age are lacking, research on middle-aged and aged mice indicated that aging hepatocytes produce 13-HODE, which inhibits catalase activity and leads to liver steatosis [33]. The concentrations of the four precursor PUFAs—EPA, DHA, AA, and LA—were orders of magnitude higher than those of the oxylipins, yet no significant age-related differences were observed. EPA and DHA are essential omega-3 fatty acids for cognitive development and anti-inflammatory processes and are significantly influenced by dietary intake, particularly fish consumption [34,35]. Other studies have shown that the plasma phospholipid concentrations of DHA and EPA are positively correlated with age in older adults [36]. The narrow age range of the participants in this study likely masked significant differences, suggesting consistent EPA and DHA levels within similar age groups. AA and LA are omega-6 fatty acids. Studies have shown that, while AA concentrations remain relatively stable with age, LA tends to decline [37,38]. In this study, LA had the highest concentration among the four precursor PUFAs, which may explain why oxylipins derived from LA were detected at higher concentrations and more easily. Although the observed differences in oxylipin and PUFA levels were not statistically significant across age groups, the established baseline concentrations in this pediatric population provide a valuable reference for future diagnostic studies.
3.5. Analysis of Oxylipin and PUFA Levels in Children’s Plasma Samples Across Sexes
A comparison of the concentrations of the four oxylipins and four PUFAs between the sexes is presented in Figure 5A. No significant sex differences were observed in oxylipin concentrations. However, boys had significantly higher EPA and AA among the PUFAs. In contrast to our findings, previous studies on fasting plasma have reported higher levels of 12,13-DiHOME in women than in men. This discrepancy may be attributed to age differences between study populations, as previous studies involved older individuals (41.3 ± 5.9 years) [39]. Additionally, studies focusing on proinflammatory exercise patterns found no differences in 9-HODE and 13-HODE levels at rest, which is consistent with our findings; however, female runners showed greater increases post-exercise than male runners [40].
A large population-based study in New Zealand involving approximately 3000 participants over the age of 15 reported lower EPA and higher DHA proportions in women [34], whereas a Scottish study involving 4114 individuals aged 40–59 years found higher DHA levels in the adipose tissue of women than in men [41]. Our study corroborates these findings, as girls had significantly lower EPA levels but no significant difference in DHA levels. Furthermore, changes in AA and LA levels contrast with other studies that have reported higher levels of these lipids in women’s total plasma [42]. Our results showed that girls had lower AA levels than boys, with no significant difference in LA, suggesting that regional, dietary, or ethnic factors may influence these lipid levels.
3.6. Analysis of Oxylipin and PUFA Levels in Children’s Plasma Samples Across BMI Categories
The concentrations of the four oxylipins and four PUFAs across various BMI ranges (underweight, normal weight, and overweight) are shown in Figure 5B. The data indicated no significant differences in oxylipin concentrations among the groups, suggesting that these metabolites may not be influenced by body weight in children aged 9–12 years. However, a significant difference was observed in the EPA levels, with overweight children exhibiting higher EPA concentrations than those of underweight children. In a study of 163 adults not taking fish oil supplements, fish consumption and BMI significantly impacted the omega-3 index; each additional fish serving per month increased the index by 0.24 units, while an increase of three BMI units decreased the index by 0.3 units [43]. Given the high fish consumption in the Japanese diet, dietary influences may outweigh the impact of BMI, leading to higher EPA levels in the overweight group. Although oxylipin levels did not vary significantly with BMI, the observed elevation of EPA in overweight children may have diagnostic relevance, particularly in dietary or metabolically driven inflammatory states, and could contribute to the development of diagnostic frameworks.
3.7. Analysis of Oxylipin and PUFA Levels in Children’s Plasma Samples in Relation to Blood Test Results
Blood tests were conducted to assess various parameters, including white blood cell count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, basophils, eosinophils, neutrophils, lymphocytes, and monocytes. Analysis of the relations between these blood parameters and the oxylipin and PUFA levels revealed significant differences (Supplementary Materials Figure S1). Although comparability between different blood parameters may be limited, a general trend was observed where oxylipins like HODE decreased as blood values such as hemoglobin and monocyte percentage increased, whereas PUFAs showed an increase with platelet count, hematocrit, white blood cell count, red blood cell count, and neutrophil percentage. Given the scarcity of studies on the relationship between lipids and blood parameters, these results support their potential use as diagnostic biomarkers in pediatric health assessments and offer an essential starting point for future research.
3.8. Comparison of Oxylipin Extraction Methods
While numerous established LC-MS/MS methods employing acidification and solid-phase extraction (SPE) have demonstrated excellent sensitivity and broad oxylipin coverage, our study proposes a simplified and precise alternative workflow specifically designed for the efficient detection of oxylipins. This method utilizes protein precipitation combined with antioxidant protection (BHT) rather than acidification and SPE, providing a faster and more user-friendly approach that is particularly suitable for high-throughput or exploratory studies.
It is important to note that although many validated SPE protocols are available, these often rely on different types of chromatographic sorbents, and the recovery of oxylipins can vary significantly depending on both the chemical nature of the compound and the specific SPE column employed. Given the structural diversity of oxylipins, including hydroxy, epoxy, and hydroperoxide derivatives—their interactions with SPE media are heterogeneous. As a result, certain oxylipins are efficiently retained and eluted on specific columns, while others may exhibit poor recovery under the same conditions. A previous comparative study involving six different SPE protocols revealed marked discrepancies in the measured plasma concentrations of certain oxylipin families [44]. This variability makes method standardization challenging, particularly when aiming for comprehensive coverage across oxylipin families.
In contrast, the protein precipitation approach offers a broader and more uniform recovery profile, as it does not rely on selective retention mechanisms. When combined with BHT, it enables the detection of both stable and labile oxylipin species.
3.9. Constraints and Limitations in This Study
In this study, we employed a methanol protein precipitation extraction method, which offers significant advantages in terms of labor and time efficiency, as well as substantial cost savings compared with that of the SPE method. However, this approach also has some drawbacks, such as lower selectivity than that of SPE, resulting in higher levels of impurities in the samples and reduced analytical sensitivity. We used BHT, a commonly used antioxidant; however, some studies have employed a combination of antioxidants, such as triphenylphosphine and ethylenediaminetetraacetic acid, which could more effectively prevent sample degradation [45]. For biological samples, we used plasma from non-fasting children. It is impractical to require fasting in children, which means that the most recent meal may have influenced the results. Due to the limited age range of our study cohort, this research may not reveal age-related differences in analyte concentrations that might be more evident in a wider age range. Further studies involving a wider age range and diverse populations are necessary to elucidate potential age-related variations.
4. Conclusions
In conclusion, we developed a simple and highly selective targeted liquid chromatography–tandem mass spectrometry method that covers 64 oxylipins; provides a foundation for large-scale quantification; exhibits good linearity, accuracy, precision, and reproducibility; and supports diagnostic research and advances insights into physiological health and biomarker discovery. The selection of fragmentation patterns for various isomers was optimized to enhance selectivity. This method was applied to plasma samples from children aged 9–12 years to provide new insights into the distribution of oxylipins and their precursor PUFAs in plasma. The relations between these concentrations and factors, such as age, sex, and BMI, were also explored, and no significant differences were observed in oxylipins with respect to these variables. However, boys had higher levels of EPA and AA than girls, and the dietary increase in EPA appeared to be more significant than the reduction in EPA associated with obesity. These findings not only provide baseline oxylipin profiles in a pediatric population but also highlight the potential utility of this method for early diagnosis and monitoring of inflammation-related conditions in children.
Supplementary Materials
The following Supplementary Materials can be downloaded at: https://www.mdpi.com/article/10.3390/diagnostics15151870/s1, Table S1: Concentrations of oxylipins and PUFAs for individual samples (ng/mL); Figure S1: Correlation of plasma oxylipins and PUFAs with blood test parameters in children; Figure S2: Extracted ion chromatogram of oxylipins and PUFAs.
Author Contributions
Y.L.: Writing—original draft, Visualization, Methodology, Formal analysis, Data curation. S.G.B.G.: Writing—review and editing, Visualization, Supervision, Resources, Methodology, Funding acquisition, Conceptualization. D.G.: Writing—review and editing, Visualization, Resources, Investigation, Formal analysis. A.I.: Writing—review and editing, Supervision, Resources, Project administration, Funding acquisition, Conceptualization. Y.A.B.: Writing—review and editing, Supervision, Resources, Investigation. R.M.K.: Writing—review and editing, Resources, Project administration. R.K.: Writing—review and editing, Resources, Project administration. H.C.: Writing—review and editing, Supervision, Resources, Project administration. S.-P.H.: Writing—review and editing, Supervision, Resources, Project administration, Funding acquisition, Conceptualization. All authors have read and agreed to the published version of the manuscript.
Funding
This study was supported by JST SPRING (Grant Number: JPMJSP2119) and KAKENHI (Grant Numbers: 21K14812, 21H04843, and 23K06861).
Institutional Review Board Statement
Ethical approval for this study was provided by the Ethics Review Board of the Faculty of Health Sciences at Hokkaido University (approval number: 22–33, granted on 15 July 2022) and the Center for Environmental and Health Sciences at Hokkaido University (approval number: 21–139, granted on 30 August 2022).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
The data is available from the corresponding author upon reasonable request.
Acknowledgments
We thank Marumi Ohno for support in obtaining the oxylipin standards used in the study.
Conflicts of Interest
The authors affirm that they have no financial interests or personal connections that could have influenced the research presented in this paper.
Abbreviations
The following abbreviations are used in this manuscript:
| LC-MS | Liquid chromatography–mass spectrometry |
| EIC | Extracted ion chromatogram |
| PUFA | Polyunsaturated fatty acid |
| LOD | Limit of detection |
| LOQ | Limit of quantification |
| DHA | Docosahexaenoic acid |
| EPA | Eicosapentaenoic acid |
| LA | Linoleic acid |
| AA | Arachidonic acid |
| EET | Epoxyeicosatrienoic acid |
| GC-MS | Gas chromatography–mass spectrometry |
| DiHOME | Dihydroxy-octadecenoic acid |
| HODE | Hydroxy-octadecadienoic acid |
| DiHDPA | Dihydroxy-docosapentaenoic acid |
| BHT | Butylated hydroxytoluene |
| RSD | Relative standard deviation |
| BMI | Body mass index |
| EpDPA | Epoxy-docosapentaenoic acid |
| HEPE | Hydroxy-eicosapentaenoic acid |
| EpETE | Epoxy-eicosatetraenoic acid |
| DiHETE | Dihydroxy-eicosatetraenoic acid |
| HDHA | Hydroxy-docosahexaenoic acid |
| HOTrE | Hydroxy-octadecatrienoic acid |
| HETE | Hydroxy-eicosatetraenoic acid |
| OxoETE | Oxo-eicosatetraenoic acid |
| MRM | Multiple reaction monitoring |
| SPE | Solid-phase extraction |
References
- Buczynski, M.W.; Dumlao, D.S.; Dennis, E.A. An Integrated Omics Analysis of Eicosanoid Biology. J. Lipid Res. 2009, 50, 1015–1038. [Google Scholar] [CrossRef] [PubMed]
- Serhan, C.N. Novel Lipid Mediators and Resolution Mechanisms in Acute Inflammation: To Resolve or Not? Am. J. Pathol. 2010, 177, 1576–1591. [Google Scholar] [CrossRef] [PubMed]
- Fischer, R.; Konkel, A.; Mehling, H.; Blossey, K.; Gapelyuk, A.; Wessel, N.; Von Schacky, C.; Dechend, R.; Muller, D.N.; Rothe, M.; et al. Dietary Omega-3 Fatty Acids Modulate the Eicosanoid Profi Le in Man Primarily via the CYP-Epoxygenase Pathway. J. Lipid Res. 2014, 55, 1150–1164. [Google Scholar] [CrossRef] [PubMed]
- Serhan, C.N. Pro-Resolving Lipid Mediators Are Leads for Resolution Physiology. Nature 2014, 510, 92–101. [Google Scholar] [CrossRef]
- Imig, J.D. Epoxides and Soluble Epoxide Hydrolase in Cardiovascular Physiology. Physiol. Rev. 2012, 92, 101–130. [Google Scholar] [CrossRef]
- Kanaoka, Y.; Boyce, J.A. Cysteinyl Leukotrienes and Their Receptors: Cellular Distribution and Function in Immune and Inflammatory Responses. J. Immunol. 2004, 173, 1503–1510. [Google Scholar] [CrossRef]
- Nayeem, M.A. Role of Oxylipins in Cardiovascular Diseases Review-Article. Acta Pharmacol. Sin. 2018, 39, 1142–1154. [Google Scholar] [CrossRef]
- Buckner, T.; Vanderlinden, L.A.; Johnson, R.K.; DeFelice, B.C.; Carry, P.M.; Seifert, J.; Waugh, K.; Dong, F.; Fiehn, O.; Clare-Salzler, M.; et al. Predictors of Oxylipins in a Healthy Pediatric Population. Pediatr. Res. 2021, 89, 1530–1540. [Google Scholar] [CrossRef]
- Jang, H.; Kim, E.G.; Kim, M.; Kim, S.Y.; Kim, Y.H.; Sohn, M.H.; Kim, K.W. Metabolomic Profiling Revealed Altered Lipid Metabolite Levels in Childhood Food Allergy. J. Allergy Clin. Immunol. 2022, 149, 1722–1731. [Google Scholar] [CrossRef]
- Schmöcker, C.; Zhang, I.W.; Kiesler, S.; Kassner, U.; Ostermann, A.I.; Steinhagen-Thiessen, E.; Schebb, N.H.; Weylandt, K.H. Effect of Omega-3 Fatty Acid Supplementation on Oxylipins in a Routine Clinical Setting. Int. J. Mol. Sci. 2018, 19, 180. [Google Scholar] [CrossRef]
- Schebb, N.H.; Ostermann, A.I.; Yang, J.; Hammock, B.D.; Hahn, A.; Schuchardt, J.P. Comparison of the Effects of Long-Chain Omega-3 Fatty Acid Supplementation on Plasma Levels of Free and Esterified Oxylipins. Prostaglandins Other Lipid Mediat. 2014, 113–115, 21–29. [Google Scholar] [CrossRef]
- Tsikas, D. Application of Gas Chromatography–Mass Spectrometry and Gas Chromatography–Tandem Mass Spectrometry to Assess in Vivo Synthesis of Prostaglandins, Thromboxane, Leukotrienes, Isoprostanes and Related Compounds in Humans. J. Chromatogr. B Biomed. Sci. Appl. 1998, 717, 201–245. [Google Scholar] [CrossRef]
- Tsikas, D.; Zoerner, A.A. Analysis of Eicosanoids by LC-MS/MS and GC-MS/MS: A Historical Retrospect and a Discussion. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2014, 964, 79–88. [Google Scholar] [CrossRef]
- Schulze, B.; Lauchli, R.; Sonwa, M.M.; Schmidt, A.; Boland, W. Profiling of Structurally Labile Oxylipins in Plants by in Situ Derivatization with Pentafluorobenzyl Hydroxylamine. Anal. Biochem. 2006, 348, 269–283. [Google Scholar] [CrossRef] [PubMed]
- Ostermann, A.I.; Koch, E.; Rund, K.M.; Kutzner, L.; Mainka, M.; Schebb, N.H. Targeting Esterified Oxylipins by LC–MS—Effect of Sample Preparation on Oxylipin Pattern. Prostaglandins Other Lipid Mediat. 2020, 146, 106384. [Google Scholar] [CrossRef] [PubMed]
- Liakh, I.; Pakiet, A.; Sledzinski, T.; Mika, A. Methods of the Analysis of Oxylipins in Biological Samples. Molecules 2020, 25, 349. [Google Scholar] [CrossRef] [PubMed]
- Zhong, H.; Xie, Q.; Li, F.; Yang, Z.; Li, K.; Luo, Q. Determination of Oxylipins and Their Precursors in Breast Milk by Solid Phase Extraction-Ultra High Performance Liquid Chromatography-Triple Quadrupole Tandem Mass Spectrometry. J. Chromatogr. A 2023, 1709, 464400. [Google Scholar] [CrossRef]
- Wolfer, A.M.; Gaudin, M.; Taylor-Robinson, S.D.; Holmes, E.; Nicholson, J.K. Development and Validation of a High-Throughput Ultrahigh-Performance Liquid Chromatography-Mass Spectrometry Approach for Screening of Oxylipins and Their Precursors. Anal. Chem. 2015, 87, 11721–11731. [Google Scholar] [CrossRef]
- Willenberg, I.; Ostermann, A.I.; Schebb, N.H. Targeted Metabolomics of the Arachidonic Acid Cascade: Current State and Challenges of LC-MS Analysis of Oxylipins. Anal. Bioanal. Chem. 2015, 407, 2675–2683. [Google Scholar] [CrossRef]
- Kishi, R.; Ikeda-Araki, A.; Miyashita, C.; Itoh, S.; Kobayashi, S.; Ait Bamai, Y.; Yamazaki, K.; Tamura, N.; Minatoya, M.; Ketema, R.M.; et al. Hokkaido Birth Cohort Study on Environment and Children’s Health: Cohort Profile 2021. Environ. Health Prev. Med. 2021, 26, 59. [Google Scholar] [CrossRef]
- Kishi, R.; Araki, A.; Minatoya, M.; Hanaoka, T.; Miyashita, C.; Itoh, S.; Kobayashi, S.; Ait Bamai, Y.; Yamazaki, K.; Miura, R.; et al. The Hokkaido Birth Cohort Study on Environment and Children’s Health: Cohort Profile—Updated 2017. Environ. Health Prev. Med. 2017, 22, 46. [Google Scholar] [CrossRef]
- Kishi, R.; Kobayashi, S.; Ikeno, T.; Araki, A.; Miyashita, C.; Itoh, S.; Sasaki, S.; Okada, E.; Kobayashi, S.; Kashino, I.; et al. Ten Years of Progress in the Hokkaido Birth Cohort Study on Environment and Children’s Health: Cohort Profile—Updated 2013. Environ. Health Prev. Med. 2013, 18, 429–450. [Google Scholar] [CrossRef]
- Kishi, R.; Sasaki, S.; Yoshioka, E.; Yuasa, M.; Sata, F.; Saijo, Y.; Kurahashi, N.; Tamaki, J.; Endo, T.; Sengoku, K.; et al. Cohort Profile: The Hokkaido Study on Environment and Children’s Health in Japan. Int. J. Epidemiol. 2011, 40, 611–618. [Google Scholar] [CrossRef]
- Zeng, Y.; Goudarzi, H.; Ait Bamai, Y.; Ketema, R.M.; Roggeman, M.; den Ouden, F.; Gys, C.; Miyashita, C.; Ito, S.; Konno, S.; et al. Exposure to Organophosphate Flame Retardants and Plasticizers Is Positively Associated with Wheeze and FeNO and Eosinophil Levels among School-Aged Children: The Hokkaido Study. Environ. Int. 2023, 181, 108278. [Google Scholar] [CrossRef] [PubMed]
- Goudarzi, H.; Ikeda-Araki, A.; Bamai, Y.A.; Ito, S.; Inao, T.; Yokota, I.; Miyashita, C.; Kishi, R.; Konno, S. Potential Determinants of T Helper 2 Markers and Their Distribution in School-Aged Children. Allergol. Int. 2023, 72, 100–106. [Google Scholar] [CrossRef] [PubMed]
- French, D. Advances in Clinical Mass Spectrometry. Adv. Clin. Chem. 2017, 79, 153–198. [Google Scholar] [PubMed]
- Gladine, C.; Ostermann, A.I.; Newman, J.W.; Schebb, N.H. MS-Based Targeted Metabolomics of Eicosanoids and Other Oxylipins: Analytical and Inter-Individual Variabilities. Free Radic. Biol. Med. 2019, 144, 72–89. [Google Scholar] [CrossRef]
- Fu, X.; Yin, H.H.; Wu, M.J.; He, X.; Jiang, Q.; Zhang, L.T.; Liu, J.Y. High Sensitivity and Wide Linearity LC-MS/MS Method for Oxylipin Quantification in Multiple Biological Samples. J. Lipid Res. 2022, 63, 100302. [Google Scholar] [CrossRef]
- Bergmann, C.B.; McReynolds, C.B.; Wan, D.; Singh, N.; Goetzman, H.; Caldwell, C.C.; Supp, D.M.; Hammock, B.D. SEH-Derived Metabolites of Linoleic Acid Drive Pathologic Inflammation While Impairing Key Innate Immune Cell Function in Burn Injury. Proc. Natl. Acad. Sci. USA 2022, 119, e2120691119. [Google Scholar] [CrossRef]
- Macêdo, A.P.A.; Muñoz, V.R.; Cintra, D.E.; Pauli, J.R. 12,13-DiHOME as a New Therapeutic Target for Metabolic Diseases. Life Sci. 2022, 290, 120229. [Google Scholar] [CrossRef]
- Chocholoušková, M.; Jirásko, R.; Vrána, D.; Gatěk, J.; Melichar, B.; Holčapek, M. Reversed Phase UHPLC/ESI-MS Determination of Oxylipins in Human Plasma: A Case Study of Female Breast Cancer. Anal. Bioanal. Chem. 2019, 411, 1239–1251. [Google Scholar] [CrossRef]
- Nagy, L.; Tontonoz, P.; Alvarez, J.G.A.; Chen, H.; Evans, R.M. Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ. Cell 1998, 93, 229–240. [Google Scholar] [CrossRef] [PubMed]
- Duan, J.; Dong, W.; Wang, G.; Xiu, W.; Pu, G.; Xu, J.; Ye, C.; Zhang, X.; Zhu, Y.; Wang, C. Senescence-Associated 13-HODE Production Promotes Age-Related Liver Steatosis by Directly Inhibiting Catalase Activity. Nat. Commun. 2023, 14, 8151. [Google Scholar] [CrossRef] [PubMed]
- Crowe, F.L.; Skeaff, C.M.; Green, T.J.; Gray, A.R. Serum N-3 Long-Chain PUFA Differ by Sex and Age in a Population-Based Survey of New Zealand Adolescents and Adults. Br. J. Nutr. 2008, 99, 168–174. [Google Scholar] [CrossRef] [PubMed]
- Dewailly, E.; Blanchet, C.; Lemieux, S.; Sauvé, L.; Gingras, S.; Ayotte, P.; Holub, B.J. N−3 Fatty Acids and Cardiovascular Disease Risk Factors among the Inuit of Nunavik. Am. J. Clin. Nutr. 2001, 74, 464–473. [Google Scholar] [CrossRef]
- De Groot, R.H.M.; Van Boxtel, M.P.J.; Schiepers, O.J.G.; Hornstra, G.; Jolles, J. Age Dependence of Plasma Phospholipid Fatty Acid Levels: Potential Role of Linoleic Acid in the Age-Associated Increase in Docosahexaenoic Acid and Eicosapentaenoic Acid Concentrations. Br. J. Nutr. 2009, 102, 1058–1064. [Google Scholar] [CrossRef]
- Harris, W.S.; Pottala, J.V.; Varvel, S.A.; Borowski, J.J.; Ward, J.N.; McConnell, J.P. Erythrocyte Omega-3 Fatty Acids Increase and Linoleic Acid Decreases with Age: Observations from 160,000 Patients. Prostaglandins Leukot. Essent. Fat. Acids 2013, 88, 257–263. [Google Scholar] [CrossRef]
- Kawabata, T.; Hirota, S.; Hirayama, T.; Adachi, N.; Hagiwara, C.; Iwama, N.; Kamachi, K.; Araki, E.; Kawashima, H.; Kiso, Y. Age-Related Changes of Dietary Intake and Blood Eicosapentaenoic Acid, Docosahexaenoic Acid, and Arachidonic Acid Levels in Japanese Men and Women. Prostaglandins Leukot. Essent. Fat. Acids 2011, 84, 131–137. [Google Scholar] [CrossRef]
- Vasan, S.K.; Noordam, R.; Gowri, M.S.; Neville, M.J.; Karpe, F.; Christodoulides, C. The Proposed Systemic Thermogenic Metabolites Succinate and 12,13-DiHOME Are Inversely Associated with Adiposity and Related Metabolic Traits: Evidence from a Large Human Cross-Sectional Study. Diabetologia 2019, 62, 2079–2087. [Google Scholar] [CrossRef]
- Nieman, D.C.; Meaney, M.P.; John, C.S.; Knagge, K.J.; Chen, H. 9- and 13-Hydroxy-Octadecadienoic Acids (9 + 13 HODE) Are Inversely Related to Granulocyte Colony Stimulating Factor and IL-6 in Runners after 2 h Running. Brain Behav. Immun. 2016, 56, 246–252. [Google Scholar] [CrossRef]
- Tavendale, R.; Lee, A.J.; Smith, W.C.S.; Tunstall-Pedoe, H. Adipose Tissue Fatty Acids in Scottish Men and Women: Results from the Scottish Heart Health Study. Atherosclerosis 1992, 94, 161–169. [Google Scholar] [CrossRef]
- Lohner, S.; Fekete, K.; Marosvölgyi, T.; Decsi, T. Gender Differences in the Long-Chain Polyunsaturated Fatty Acid Status: Systematic Review of 51 Publications. Ann. Nutr. Metab. 2013, 62, 98–112. [Google Scholar] [CrossRef]
- Sands, S.A.; Reid, K.J.; Windsor, S.L.; Harris, W.S. The Impact of Age, Body Mass Index, and Fish Intake on the EPA and DHA Content of Human Erythrocytes. Lipids 2005, 40, 343–347. [Google Scholar] [CrossRef]
- Ostermann, A.I.; Willenberg, I.; Schebb, N.H. Comparison of sample preparation methods for the quantitative analysis of eicosanoids and other oxylipins in plasma by means of LC-MS/MS. Anal. Bioanal. Chem. 2015, 407, 1403–1414. [Google Scholar] [CrossRef]
- Zhang, Z.; Hennebelle, M.; Emami, S.; Taha, A.Y. Effects of Potato Processing and Frying on Oxylipin Concentrations. ACS Food Sci. Technol. 2021, 1, 1436–1443. [Google Scholar] [CrossRef]
Figure 1.
Conversion of PUFAs (AA, LA, DHA, and EPA) into oxylipins. DiHOME: Dihydroxy-octadecenoic acid; HODE: hydroxy-octadecadienoic acid; EPA: eicosapentaenoic acid; LA: linoleic acid; AA: arachidonic acid; PUFA: polyunsaturated fatty acid; CYP450: cytochrome P450; OxoETE: oxo-eicosatetraenoic acid; HETE: hydroxy-eicosatetraenoic acid; DiHDPA: dihydroxy-docosapentaenoic acid. “20:4 n-6” refers to a 20-carbon omega-6 fatty acid with four double bonds and “22:6 n-3” refers to a 22-carbon omega-3 fatty acid with six double bonds.
Figure 1.
Conversion of PUFAs (AA, LA, DHA, and EPA) into oxylipins. DiHOME: Dihydroxy-octadecenoic acid; HODE: hydroxy-octadecadienoic acid; EPA: eicosapentaenoic acid; LA: linoleic acid; AA: arachidonic acid; PUFA: polyunsaturated fatty acid; CYP450: cytochrome P450; OxoETE: oxo-eicosatetraenoic acid; HETE: hydroxy-eicosatetraenoic acid; DiHDPA: dihydroxy-docosapentaenoic acid. “20:4 n-6” refers to a 20-carbon omega-6 fatty acid with four double bonds and “22:6 n-3” refers to a 22-carbon omega-3 fatty acid with six double bonds.
Figure 2.
Liquid chromatography–tandem mass spectrometry (LC-MS/MS) methodology for quantitative analysis of children’s plasma samples.
Figure 2.
Liquid chromatography–tandem mass spectrometry (LC-MS/MS) methodology for quantitative analysis of children’s plasma samples.
Figure 3.
MS/MS spectra and EICs of HETE isomers and oxylipins/PUFAs in children’s plasma samples and standards. (A) The MS/MS spectra of four HETE isomers, including (±)5-HETE, (±)8-HETE, (±)11-HETE, and (±)15-HETE, are presented, with each spectrum highlighting the fragmentation pattern and characteristic ions (*), which assist in identifying these isomers based on their distinct fragmentation pathways. (B) The EICs of selected oxylipins and PUFAs from plasma samples of children aged 9–12 years (a) and corresponding standards (b) are shown. The compounds analyzed include (±)12(13)-DiHOME, (±)9(10)DiHOME, 9(S)-HODE, 13(S)-HODE, EPA, DHA, AA, and LA. The chromatograms demonstrated the retention times and peak shapes of these analytes, illustrating the ability of this method to resolve and quantify these compounds in biological samples. HODE: Hydroxy-octadecadienoic acid; EPA: eicosapentaenoic acid; LA: linoleic acid; AA: arachidonic acid; PUFA: polyunsaturated fatty acid; HETE: hydroxy-eicosatetraenoic acid; DiHOME: dihydroxy-octadecenoic acid.
Figure 3.
MS/MS spectra and EICs of HETE isomers and oxylipins/PUFAs in children’s plasma samples and standards. (A) The MS/MS spectra of four HETE isomers, including (±)5-HETE, (±)8-HETE, (±)11-HETE, and (±)15-HETE, are presented, with each spectrum highlighting the fragmentation pattern and characteristic ions (*), which assist in identifying these isomers based on their distinct fragmentation pathways. (B) The EICs of selected oxylipins and PUFAs from plasma samples of children aged 9–12 years (a) and corresponding standards (b) are shown. The compounds analyzed include (±)12(13)-DiHOME, (±)9(10)DiHOME, 9(S)-HODE, 13(S)-HODE, EPA, DHA, AA, and LA. The chromatograms demonstrated the retention times and peak shapes of these analytes, illustrating the ability of this method to resolve and quantify these compounds in biological samples. HODE: Hydroxy-octadecadienoic acid; EPA: eicosapentaenoic acid; LA: linoleic acid; AA: arachidonic acid; PUFA: polyunsaturated fatty acid; HETE: hydroxy-eicosatetraenoic acid; DiHOME: dihydroxy-octadecenoic acid.
Figure 4.
Quantitative amounts of oxylipins and PUFAs in boys (A) and girls (B) of different age groups (the Kruskal–Wallis test followed by Dunn’s multiple comparisons test was used for comparative analysis of the values, presented as mean ± standard error of the mean). HODE: Hydroxy-octadecadienoic acid; EPA: eicosapentaenoic acid; LA: linoleic acid; AA: arachidonic acid; PUFA: polyunsaturated fatty acid; DiHOME: dihydroxy-octadecenoic acid.
Figure 4.
Quantitative amounts of oxylipins and PUFAs in boys (A) and girls (B) of different age groups (the Kruskal–Wallis test followed by Dunn’s multiple comparisons test was used for comparative analysis of the values, presented as mean ± standard error of the mean). HODE: Hydroxy-octadecadienoic acid; EPA: eicosapentaenoic acid; LA: linoleic acid; AA: arachidonic acid; PUFA: polyunsaturated fatty acid; DiHOME: dihydroxy-octadecenoic acid.
Figure 5.
Oxylipin and PUFA levels in plasma of children aged 9–12 years classified by sex and body mass index categories. (A) Comparison of oxylipin and PUFA levels between boys and girls. Plasma concentrations of (±)12(13)-DiHOME, (±)9(10)-DiHOME, 9(S)-HODE, 13(S)-HODE, EPA, DHA, AA, and LA were measured. Significant differences were observed in the levels of EPA and AA, with boys showing higher levels compared with those of girls (the Kolmogorov–Smirnov test was conducted for comparative analysis of the values presented as mean ± standard error of the mean, with significance set at * p < 0.05). (B) Comparison of oxylipin and PUFA levels among the different body mass index categories (U, underweight; N, normal weight; O, overweight). Plasma concentrations of (±)12(13)-DiHOME, (±)9(10)-DiHOME, 9(S)-HODE, 13(S)-HODE, EPA, DHA, AA, and LA were analyzed. Significant differences were observed in the EPA levels, with underweight children showing lower EPA concentrations than those of overweight children (the Kruskal–Wallis test followed by Dunn’s multiple comparisons test was used for comparative analysis of the values, presented as mean ± standard error of the mean, with significance levels denoted as * p < 0.05). HODE: Hydroxy-octadecadienoic acid; EPA: eicosapentaenoic acid; LA: linoleic acid; AA: arachidonic acid; PUFA: polyunsaturated fatty acid; DiHOME: dihydroxy-octadecenoic acid.
Figure 5.
Oxylipin and PUFA levels in plasma of children aged 9–12 years classified by sex and body mass index categories. (A) Comparison of oxylipin and PUFA levels between boys and girls. Plasma concentrations of (±)12(13)-DiHOME, (±)9(10)-DiHOME, 9(S)-HODE, 13(S)-HODE, EPA, DHA, AA, and LA were measured. Significant differences were observed in the levels of EPA and AA, with boys showing higher levels compared with those of girls (the Kolmogorov–Smirnov test was conducted for comparative analysis of the values presented as mean ± standard error of the mean, with significance set at * p < 0.05). (B) Comparison of oxylipin and PUFA levels among the different body mass index categories (U, underweight; N, normal weight; O, overweight). Plasma concentrations of (±)12(13)-DiHOME, (±)9(10)-DiHOME, 9(S)-HODE, 13(S)-HODE, EPA, DHA, AA, and LA were analyzed. Significant differences were observed in the EPA levels, with underweight children showing lower EPA concentrations than those of overweight children (the Kruskal–Wallis test followed by Dunn’s multiple comparisons test was used for comparative analysis of the values, presented as mean ± standard error of the mean, with significance levels denoted as * p < 0.05). HODE: Hydroxy-octadecadienoic acid; EPA: eicosapentaenoic acid; LA: linoleic acid; AA: arachidonic acid; PUFA: polyunsaturated fatty acid; DiHOME: dihydroxy-octadecenoic acid.
Table 1.
Mass spectrometry (MS) parameters of oxylipins, polyunsaturated fatty acids (PUFAs), and internal standard.
Table 1.
Mass spectrometry (MS) parameters of oxylipins, polyunsaturated fatty acids (PUFAs), and internal standard.
| Analytes | Precursor Ion [M−H]− (m/z) | Product Ion (m/z) | Collision Energy (eV) | Tube Lens (V) |
|---|---|---|---|---|
| Prostaglandin F3α | 351.218 | 193.1 | 20 | 65 |
| Prostaglandin E3 | 349.202 | 269.2 | 15 | 60 |
| 8-iso Prostaglandin F2α | 353.234 | 193.0 | 27 | 81 |
| (±)5-iPF2α-VI | 353.233 | 335.1 | 18 | 75 |
| Prostaglandin F2α | 353.232 | 193.1 | 22 | 89 |
| (±)5(6)-DiHETE | 335.221 | 145.0 | 15 | 61 |
| (±)19(20)-DiHDPA | 361.236 | 229.4 | 20 | 63 |
| (±)13(14)-DiHDPA | 361.238 | 233.1 | 15 | 65 |
| 9(S)-HOTrE | 293.211 | 171.1 | 15 | 64 |
| (±)16(17)-DiHDPA | 361.237 | 193.1 | 15 | 67 |
| 13(S)-HOTrE | 293.212 | 195.0 | 15 | 66 |
| (±)18-HEPE | 317.212 | 215.2 | 15 | 65 |
| (±)10(11)-DiHDPA | 361.239 | 153.2 | 15 | 63 |
| 13(S)-HODE | 295.228 | 195.0 | 15 | 66 |
| 9(S)-HODE | 295.227 | 171.0 | 15 | 65 |
| 13-OxoODE | 293.214 | 113.0 | 15 | 73 |
| (±)17(18)-EpETE | 317.209 | 215.0 | 15 | 66 |
| (±)20-HDHA | 343.226 | 285.0 | 15 | 70 |
| 9-OxoODE | 293.213 | 185.0 | 20 | 68 |
| (±)15-HETE | 319.229 | 219.1 | 16 | 67 |
| 15-OxoETE | 317.213 | 139.0 | 17 | 75 |
| (±)8-HDHA | 343.227 | 125.0 | 20 | 62 |
| (±)14(15)-EpETE | 317.211 | 248.0 | 15 | 65 |
| (±)16-HDHA | 343.230 | 261.0 | 15 | 65 |
| 17(S)-HDHA | 343.229 | 245.0 | 15 | 63 |
| (±)11-HETE | 319.228 | 167.0 | 18 | 74 |
| (±)13-HDHA | 343.228 | 221.0 | 15 | 69 |
| (±)11(12)-EpETE | 317.210 | 195.0 | 15 | 62 |
| (±)8(9)-EpETE | 317.214 | 155.0 | 15 | 69 |
| (±)17(18)-DiHETE | 335.221 | 203.0 | 15 | 63 |
| (±)11(12)-DiHETE | 335.222 | 167.0 | 15 | 67 |
| (±)8(9)-DiHETE | 335.223 | 185.0 | 15 | 64 |
| (±)14(15)-DiHETE | 335.224 | 111.0 | 20 | 68 |
| (±)12(13)-DiHOME | 313.238 | 183.0 | 20 | 62 |
| (±)9(10)DiHOME | 313.239 | 201.0 | 20 | 64 |
| 13(S)-HOTrE(γ) | 293.212 | 193.0 | 15 | 67 |
| 15(S)-HEPE | 317.214 | 219.1 | 20 | 67 |
| (±)11-HEPE | 317.212 | 195.1 | 15 | 63 |
| (±)7(8)-DiHDPA | 361.238 | 127.1 | 20 | 62 |
| (±)8-HEPE | 317.210 | 155.1 | 15 | 62 |
| 12(S)-HEPE | 317.213 | 207.1 | 17 | 75 |
| (±)9-HEPE | 317.211 | 123.1 | 15 | 66 |
| 5(S)-HEPE | 317.209 | 129.1 | 20 | 68 |
| (±)10-HDHA | 343.226 | 181.0 | 15 | 66 |
| 14(S)-HDHA | 343.230 | 205.0 | 15 | 67 |
| (±)8-HETE | 319.227 | 155.0 | 16 | 60 |
| (±)12-HETE | 319.229 | 135.0 | 17 | 71 |
| 12-OxoETE | 317.216 | 153.0 | 17 | 72 |
| (±)11-HDHA | 343.223 | 165.0 | 15 | 62 |
| (±)7-HDHA | 343.224 | 141.0 | 15 | 64 |
| (±)19(20)-EpDPA | 343.225 | 241.6 | 15 | 66 |
| (±)5-HETE | 319.226 | 115.0 | 15 | 60 |
| (±)12(13)-EpOME | 295.228 | 195.0 | 15 | 66 |
| (±)9(10)-EpOME | 295.227 | 171.0 | 15 | 65 |
| (±)14(15)-EET | 319.230 | 219.1 | 14 | 62 |
| (±)4-HDHA | 343.231 | 101.0 | 15 | 61 |
| (±)16(17)-EpDPA | 343.232 | 274.4 | 15 | 69 |
| 5-OxoETE | 317.215 | 203.2 | 20 | 79 |
| (±)5(6)-EET | 319.225 | 191.3 | 15 | 74 |
| (±)13(14)-EpDPA | 343.227 | 161.3 | 15 | 70 |
| (±)11(12)-EET | 319.228 | 208.0 | 15 | 75 |
| (±)10(11)-EpDPA | 343.228 | 153.2 | 15 | 61 |
| (±)8(9)-EET | 319.231 | 155.0 | 16 | 79 |
| (±)7(8)-EpDPA | 343.229 | 112.8 | 15 | 65 |
| EPA | 301.217 | 257.2 | 16 | 90 |
| DHA | 327.233 | 283.2 | 14 | 92 |
| AA | 303.233 | 259.3 | 18 | 91 |
| LA | 279.233 | 261.1 | 23 | 91 |
| AA-d8 | 311.283 | 267.3 | 16 | 62 |
| 12(S)-HETE-d8 | 327.278 | 184.0 | 15 | 64 |
| 15(S)-HETE-d8 | 327.277 | 226.0 | 15 | 67 |
| 5(S)-HETE-d8 | 327.279 | 116.0 | 15 | 65 |
| 8-isoProstaglandin F2α-d4 | 357.259 | 197.0 | 27 | 76 |
Table 2.
Retention time, limit of detection (LOD), limit of quantification (LOQ), and linearity of oxylipins and poly-unsaturated fatty acids (PUFAs).
Table 2.
Retention time, limit of detection (LOD), limit of quantification (LOQ), and linearity of oxylipins and poly-unsaturated fatty acids (PUFAs).
| Analytes | R.T. (min) | LOD (pg) | LOQ (pg) | R2 | Linear Range (pg) | Slope |
|---|---|---|---|---|---|---|
| Prostaglandin F3α | 12.36 | 5 | 10 | 0.9966 | 5–1000 | 0.01011 |
| Prostaglandin E3 | 12.48 | 0.5 | 1 | 0.9993 | 1–1000 | 0.09813 |
| 8-iso Prostaglandin F2α | 12.52 | 1 | 2.5 | 0.9967 | 2.5–1000 | 0.05235 |
| (±)5-iPF2α-VI | 12.68 | 2.5 | 5 | 0.9988 | 5–1000 | 0.05519 |
| Prostaglandin F2α | 12.94 | 0.5 | 1 | 0.995 | 1–1000 | 0.04031 |
| (±)17(18)-DiHETE | 16.15 | 5 | 10 | 0.995 | 10–1000 | 0.0052 |
| (±)11(12)-DiHETE | 16.85 | 0.5 | 1 | 0.9979 | 1–1000 | 0.03615 |
| (±)8(9)-DiHETE | 17.21 | 1 | 2.5 | 0.9995 | 2.5–1000 | 0.0175 |
| (±)14(15)-DiHETE | 17.22 | 1 | 2.5 | 0.9925 | 2.5–1000 | 0.0067 |
| (±)12(13)-DiHOME | 17.3 | 0.5 | 1 | 0.9973 | 1–1000 | 0.08608 |
| (±)9(10)DiHOME | 17.79 | 0.5 | 1 | 0.9987 | 1–1000 | 0.13526 |
| (±)5(6)-DiHETE | 18.16 | 2.5 | 5 | 0.995 | 5–1000 | 0.05946 |
| (±)19(20)-DiHDPA | 18.57 | 2.5 | 5 | 0.9921 | 5–1000 | 0.00771 |
| (±)13(14)-DiHDPA | 19.17 | 2.5 | 5 | 0.9988 | 5–1000 | 0.01391 |
| 9(S)-HOTrE | 19.3 | 1 | 2.5 | 0.9945 | 2.5–1000 | 0.02924 |
| (±)16(17)-DiHDPA | 19.52 | 0.5 | 1 | 0.9987 | 1–1000 | 0.02587 |
| 13(S)-HOTrE | 19.66 | 2.5 | 5 | 0.9955 | 2.5–1000 | 0.01063 |
| (±)18-HEPE | 19.81 | 1 | 2.5 | 0.9995 | 2.5–1000 | 0.02875 |
| (±)10(11)-DiHDPA | 19.89 | 1 | 2.5 | 0.9979 | 2.5–1000 | 0.02351 |
| 13(S)-HOTrE(γ) | 20.14 | 1 | 2.5 | 0.9993 | 2.5–1000 | 0.04092 |
| 15(S)-HEPE | 20.64 | 2.5 | 5 | 0.996 | 5–1000 | 0.00493 |
| (±)11-HEPE | 20.75 | 1 | 2.5 | 0.9989 | 2.5–1000 | 0.02179 |
| (±)7(8)-DiHDPA | 20.84 | 5 | 10 | 0.9953 | 10–1000 | 0.02686 |
| (±)8-HEPE | 20.98 | 2.5 | 5 | 0.9959 | 5–1000 | 0.1022 |
| 12(S)-HEPE | 21.23 | 25 | 50 | 0.9926 | 50–1000 | 0.00735 |
| (±)9-HEPE | 21.46 | 5 | 10 | 0.9947 | 10–1000 | 0.00917 |
| 5(S)-HEPE | 21.93 | 1 | 2.5 | 0.9958 | 2.5–1000 | 0.06759 |
| 13(S)-HODE | 22.43 | 0.5 | 1 | 0.9977 | 1–1000 | 0.05315 |
| 9(S)-HODE | 22.55 | 0.25 | 0.5 | 0.9991 | 0.5–1000 | 0.07289 |
| 13-OxoODE | 22.67 | 2.5 | 5 | 0.9954 | 5–1000 | 0.00611 |
| (±)17(18)-EpETE | 22.71 | 2.5 | 5 | 0.9978 | 5–1000 | 0.027 |
| (±)20-HDHA | 22.97 | 10 | 25 | 0.9967 | 25–1000 | 0.00982 |
| 9-OxoODE | 23.28 | 2.5 | 5 | 0.9974 | 5–1000 | 0.06133 |
| (±)15-HETE | 23.28 | 2.5 | 5 | 0.9988 | 5–1000 | 0.0156 |
| 15-OxoETE | 23.45 | 10 | 25 | 0.9983 | 25–1000 | 0.00851 |
| (±)8-HDHA | 23.54 | 25 | 50 | 0.9818 | 50–1000 | 0.00401 |
| (±)14(15)-EpETE | 23.56 | 2.5 | 5 | 0.994 | 5–1000 | 0.01266 |
| (±)16-HDHA | 23.56 | 25 | 50 | 0.9965 | 50–1000 | 0.00359 |
| 17(S)-HDHA | 23.68 | 5 | 10 | 0.9988 | 10–1000 | 0.00847 |
| (±)11-HETE | 23.75 | 0.5 | 1 | 0.9993 | 1–1000 | 0.06515 |
| (±)13-HDHA | 23.79 | 1 | 2.5 | 0.9904 | 2.5–1000 | 0.01295 |
| (±)11(12)-EpETE | 23.8 | 5 | 10 | 0.9924 | 10–1000 | 0.00641 |
| (±)8(9)-EpETE | 23.92 | 2.5 | 5 | 0.9983 | 5–1000 | 0.03193 |
| (±)10-HDHA | 24.02 | 2.5 | 5 | 0.9995 | 5–1000 | 0.01167 |
| 14(S)-HDHA | 24.03 | 1 | 2.5 | 0.9997 | 2.5–1000 | 0.01364 |
| (±)8-HETE | 24.1 | 1 | 2.5 | 0.9989 | 2.5–1000 | 0.07756 |
| (±)12-HETE | 24.11 | 5 | 10 | 0.996 | 10–1000 | 0.00474 |
| 12-OxoETE | 24.18 | 2.5 | 5 | 0.9981 | 5–1000 | 0.01544 |
| (±)11-HDHA | 24.26 | 2.5 | 5 | 0.9929 | 2.5–1000 | 0.00515 |
| (±)7-HDHA | 24.37 | 2.5 | 5 | 0.9981 | 5–1000 | 0.03476 |
| (±)5-HETE | 24.57 | 0.625 | 1.5625 | 0.9972 | 1.5625–1000 | 0.05294 |
| (±)12(13)-EpOME | 24.76 | 0.1 | 0.25 | 0.9974 | 0.25–1000 | 0.15922 |
| (±)19(20)-EpDPA | 24.83 | 5 | 10 | 0.9923 | 10–1000 | 0.00335 |
| (±)9(10)-EpOME | 24.88 | 1 | 2.5 | 0.9997 | 2.5–1000 | 0.09169 |
| (±)14(15)-EET | 24.94 | 2.5 | 5 | 0.9986 | 2.5–1000 | 0.01247 |
| (±)4-HDHA | 25.08 | 2.5 | 5 | 0.9986 | 5–1000 | 0.06812 |
| (±)16(17)-EpDPA | 25.2 | 2.5 | 5 | 0.9987 | 5–1000 | 0.00355 |
| 5-OxoETE | 25.28 | 5 | 10 | 0.9959 | 10–1000 | 0.05103 |
| (±)13(14)-EpDPA | 25.33 | 5 | 10 | 0.9936 | 10–1000 | 0.00624 |
| (±)11(12)-EET | 25.42 | 10 | 25 | 0.9949 | 25–1000 | 0.00654 |
| (±)10(11)-EpDPA | 25.45 | 2.5 | 5 | 0.9966 | 5–1000 | 0.02115 |
| (±)8(9)-EET | 25.54 | 10 | 25 | 0.9962 | 25–1000 | 0.02073 |
| (±)7(8)-EpDPA | 25.58 | 10 | 25 | 0.9979 | 25–1000 | 0.00974 |
| (±)5(6)-EET | 25.66 | 5 | 10 | 0.9943 | 10–1000 | 0.01971 |
| EPA | 26.78 | 10 | 20 | 0.9992 | 20–200,000 | 0.00549 |
| DHA | 27.51 | 5 | 10 | 0.9998 | 10–200,000 | 0.01596 |
| AA | 27.71 | 10 | 20 | 0.9997 | 20–200,000 | 0.00134 |
| LA | 27.81 | 10 | 20 | 0.9976 | 20–200,000 | 0.00043 |
Table 3.
Recovery and matrix effects of oxylipins and polyunsaturated fatty acids (PUFAs).
| 50 ng/mL | 75 ng/mL | 100 ng/mL | ||||
|---|---|---|---|---|---|---|
| Analytes | Recovery | Matrix Effect (%) | Recovery | Matrix Effect (%) | Recovery | Matrix Effect (%) |
| (%) | (%) | (%) | ||||
| AA * | 92.5 | 95.5 | 96 | 98.5 | 106.1 | 94.9 |
| (±)15-HETE | 121.9 | 97.3 | 98.8 | 103.2 | 94.6 | 93.3 |
| 5-OxoETE | 99 | 110.7 | 100.6 | 101.9 | 100.3 | 116.8 |
| PGF2α | 99.4 | 100.9 | 101 | 104.5 | 105.4 | 105.7 |
| (±)11(12)-EET | 92.4 | 95.9 | 108 | 88.8 | 121.3 | 115.8 |
| LA * | 92.2 | 89.7 | 114.1 | 108.3 | 114.5 | 100.3 |
| 13(S)-HODE | 102.9 | 103.8 | 97.2 | 110.3 | 102 | 96.7 |
| 13-OxoODE | 84.2 | 110.5 | 95.8 | 109.1 | 99.5 | 102.9 |
| (±)9(10)-DiHOME | 84.4 | 103 | 93.7 | 104.4 | 92.8 | 109.3 |
| (±)9(10)-EpOME | 93.8 | 87.4 | 83.7 | 87.5 | 85.8 | 85.8 |
| DHA * | 89.5 | 93.6 | 103.6 | 106.1 | 116.3 | 105.8 |
| (±)4-HDHA | 104.5 | 98.1 | 122.1 | 94.5 | 106.4 | 107.3 |
| (±)13(14)-EpDPA | 87.2 | 96.1 | 82.6 | 91.4 | 82.5 | 84.3 |
| (±)7(8)-DiHDPA | 90.3 | 101.6 | 98.3 | 98.7 | 97.1 | 113.4 |
| EPA * | 92.7 | 94.2 | 98.6 | 99.3 | 108.7 | 95.4 |
| (±)11-HEPE | 95 | 102.8 | 96.3 | 104.5 | 94.6 | 107.7 |
| (±)17(18)-EpETE | 92.7 | 99.7 | 107 | 111.7 | 102.8 | 112.2 |
| (±)17(18)-DiHETE | 98.2 | 102.5 | 99.2 | 106.2 | 99.9 | 108 |
| 13(S)-HOTrE | 89.5 | 99.4 | 100.8 | 113.8 | 98.9 | 106.9 |
| Mean ± SD (total) | 90 ± 13 | 97 ± 11 | 95 ± 12 | 98 ± 14 | 95 ± 13 | 90 ± 18 |
* The concentrations of PUFAs are as follows: low at 5 μg/mL, medium at 10 μg/mL, and high at 20 μg/mL.
Table 4.
Accuracy and precision of oxylipins and polyunsaturated fatty acids (PUFAs).
| 50 ng/mL | 75 ng/mL | 100 ng/mL | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intra-Day (%) | Inter-Day (%) | Intra-Day (%) | Inter-Day (%) | Intra-Day (%) | Inter-Day (%) | |||||||
| Analytes | Accuracy | Precision | Accuracy | Precision | Accuracy | Precision | Accuracy | Precision | Accuracy | Precision | Accuracy | Precision |
| AA * | 73.9 | 3.7 | 85.0 | 1.8 | 75.7 | 4.0 | 82.9 | 3.5 | 90.6 | 4.2 | 77.6 | 2.0 |
| 15HETE | 103.7 | 9.4 | 75.2 | 8.5 | 91.0 | 7.3 | 81.4 | 8.2 | 84.8 | 4.5 | 78.5 | 4.4 |
| 5-OxoETE | 93.6 | 8.1 | 93.5 | 5.6 | 90.3 | 7.6 | 89.3 | 6.8 | 89.9 | 2.6 | 85.8 | 6.0 |
| PGF2α | 86.4 | 3.5 | 87.0 | 2.1 | 90.7 | 1.5 | 86.0 | 1.2 | 98.3 | 1.9 | 92.5 | 0.8 |
| (±)11(12)-EET | 98.4 | 6.5 | 99.7 | 9.4 | 81.9 | 14.4 | 87.7 | 12.5 | 88.2 | 10.8 | 76.7 | 6.9 |
| LA * | 75.7 | 6.4 | 83.4 | 5.0 | 79.6 | 4.2 | 82.3 | 6.4 | 93.6 | 3.3 | 76.9 | 2.1 |
| 13(S)-HODE | 94.2 | 5.3 | 78.0 | 2.1 | 89.0 | 1.4 | 80.4 | 4.5 | 89.9 | 1.9 | 85.3 | 5.5 |
| 13-OxoODE | 68.5 | 5.2 | 79.0 | 2.8 | 81.5 | 5.3 | 81.1 | 3.6 | 83.3 | 5.4 | 82.5 | 7.3 |
| (±)9(10)DiHOME | 72.5 | 4.4 | 76.4 | 4.2 | 76.8 | 2.8 | 75.4 | 2.9 | 75.0 | 0.6 | 75.1 | 4.9 |
| (±)9(10)-EpOME | 89.0 | 10.2 | 91.7 | 8.0 | 81.9 | 14.0 | 80.6 | 4.9 | 79.6 | 11.6 | 79.5 | 5.5 |
| DHA * | 76.9 | 3.8 | 88.9 | 3.0 | 87.4 | 2.0 | 99.5 | 2.6 | 110.7 | 5.3 | 92.9 | 3.9 |
| (±)4-HDHA | 104.5 | 12.4 | 87.0 | 0.9 | 111.0 | 8.1 | 86.4 | 4.7 | 92.0 | 11.4 | 76.5 | 6.6 |
| (±)13(14)-EpDPA | 79.0 | 12.9 | 78.6 | 12.8 | 77.8 | 7.1 | 76.7 | 6.2 | 83.4 | 7.6 | 74.5 | 6.6 |
| (±)7(8)-DiHDPA | 80.9 | 4.6 | 93.5 | 11.4 | 89.9 | 9.7 | 85.6 | 5.5 | 86.6 | 2.5 | 88.1 | 4.4 |
| EPA * | 79.4 | 4.1 | 88.9 | 1.5 | 82.2 | 3.2 | 90.0 | 3.7 | 104.5 | 3.0 | 85.7 | 2.1 |
| (±)11-HEPE | 80.6 | 10.3 | 83.8 | 4.1 | 80.1 | 1.6 | 77.5 | 4.1 | 77.5 | 2.7 | 78.6 | 4.2 |
| (±)17(18)-EpETE | 97.3 | 14.8 | 104.6 | 8.3 | 105.4 | 4.1 | 101.9 | 7.5 | 102.4 | 6.6 | 100.8 | 4.4 |
| (±)17(18)-DiHETE | 91.7 | 2.1 | 91.4 | 5.2 | 88.2 | 9.1 | 86.0 | 3.8 | 90.1 | 1.4 | 92.2 | 4.9 |
| 13(S)-HOTrE | 81.2 | 10.8 | 82.2 | 2.5 | 88.9 | 5.4 | 89.0 | 2.4 | 86.3 | 4.3 | 89.5 | 3.6 |
* The concentrations of PUFAs are as follows: low at 5 μg/mL, medium at 10 μg/mL, and high at 20 μg/mL.
Table 5.
Concentrations of plasma oxylipins and polyunsaturated fatty acids (PUFAs) in boys and girls categorized by age groups. Values are presented as median (interquartile range).
Table 5.
Concentrations of plasma oxylipins and polyunsaturated fatty acids (PUFAs) in boys and girls categorized by age groups. Values are presented as median (interquartile range).
| Boys (ng/mL) | Girls (ng/mL) | |||||||
|---|---|---|---|---|---|---|---|---|
| Analytes | 9 y | 10 y | 11 y | 12 y | 9 y | 10 y | 11 y | 12 y |
| (Detection Frequency) | ||||||||
| (±)12(13)-DiHOME | 0.4 | 0.5 | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 |
| (83.30%) | (0.2–0.7) | (0.2–0.8) | (0.2–0.7) | (0.1–0.7) | (0.2–0.8) | (0.2–0.6) | (0.2–0.5) | (0.2–0.9) |
| (±)9(10)-DiHOME | 0.3 | 0.6 | 0.4 | 0.4 | 0.4 | 0.3 | 0.2 | 0.6 |
| (89.20%) | (0.1–0.8) | (0.2–0.9) | (0.3–0.6) | (0.2–0.9) | (0.2–0.9) | (0.2–0.8) | (0.1–0.7) | (0.3–1.0) |
| 13(S)-HODE | 0.2 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.2 |
| (58.20%) | (0.0–0.3) | (0.0–0.3) | (0.0–0.2) | (0.0–0.3) | (0.0–0.4) | (0.0–0.2) | (0.0–0.6) | (0.0–0.3) |
| 9(S)-HODE | 0.2 | 0.3 | 0.1 | 0.3 | 0.4 | 0.2 | 0.3 | 0.2 |
| (85.40%) | (0.1–0.6) | (0.1–0.5) | (0.1–0.6) | (0.1–0.5) | (0.2–0.6) | (0.1–0.7) | (0.1–0.6) | (0.1–0.7) |
| EPA | 165 | 178 | 165 | 162 | 145 | 142 | 163 | 158 |
| (100%) | (100–279) | (108–241) | (108–264) | (124–228) | (101–196) | (106–222) | (108–181) | (90–200) |
| DPA | 908 | 926 | 968 | 1111 | 905 | 915 | 868 | 1004 |
| (100%) | (738–1320) | (744–1333) | (765–1325) | (727–1304) | (715–1191) | (697–1295) | (729–1105) | (737–1387) |
| AA | 2315 | 2185 | 2176 | 2525 | 2050 | 2064 | 1913 | 2117 |
| (100%) | (1745–2756) | (1680–2628) | (1658–2708) | (1398–3034) | (1663–2407) | (1756–2562) | (1453–2111) | (1887–2406) |
| LA | 5779 | 5465 | 5675 | 5905 | 5993 | 6544 | 5761 | 5866 |
| (100%) | (4415–7944) | (4841–7751) | (4862–7932) | (3780–8238) | (4398–8514) | (5210–8584) | (4444–6546) | (4716–8438) |
DiHOME: Dihydroxy-octadecenoic acid; HODE: hydroxy-octadecadienoic acid; EPA: eicosapentaenoic acid; LA: linoleic acid; AA: arachidonic acid.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Li, Y.; Gowda, S.G.B.; Gowda, D.; Ikeda, A.; Bamai, Y.A.; Ketema, R.M.; Kishi, R.; Chiba, H.; Hui, S.-P. Development of a Liquid Chromatography–Tandem Mass Spectrometry Method for Oxylipin Analysis and Its Application to Children’s Plasma. Diagnostics 2025, 15, 1870. https://doi.org/10.3390/diagnostics15151870
AMA Style
Li Y, Gowda SGB, Gowda D, Ikeda A, Bamai YA, Ketema RM, Kishi R, Chiba H, Hui S-P. Development of a Liquid Chromatography–Tandem Mass Spectrometry Method for Oxylipin Analysis and Its Application to Children’s Plasma. Diagnostics. 2025; 15(15):1870. https://doi.org/10.3390/diagnostics15151870
Chicago/Turabian StyleLi, Yonghan, Siddabasave Gowda B. Gowda, Divyavani Gowda, Atsuko Ikeda, Yu Ait Bamai, Rahel Mesfin Ketema, Reiko Kishi, Hitoshi Chiba, and Shu-Ping Hui. 2025. "Development of a Liquid Chromatography–Tandem Mass Spectrometry Method for Oxylipin Analysis and Its Application to Children’s Plasma" Diagnostics 15, no. 15: 1870. https://doi.org/10.3390/diagnostics15151870
APA StyleLi, Y., Gowda, S. G. B., Gowda, D., Ikeda, A., Bamai, Y. A., Ketema, R. M., Kishi, R., Chiba, H., & Hui, S.-P. (2025). Development of a Liquid Chromatography–Tandem Mass Spectrometry Method for Oxylipin Analysis and Its Application to Children’s Plasma. Diagnostics, 15(15), 1870. https://doi.org/10.3390/diagnostics15151870
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
